Praxis Precision Medicines (PRAX) Cash from Investing Activities (2021 - 2026)

Praxis Precision Medicines' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$344.3 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 574.2% year-over-year to -$344.3 million in Q1 2026; TTM through Mar 2026 was -$604.4 million, a 190.09% decrease from a year earlier, with the FY2025 full-year figure at -$311.1 million, down 25.21% from the prior year.
• Cash from Investing Activities declined to -$344.3 million in Q1 2026 per PRAX's latest filing, from -$328.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $50.4 million in Q3 2025 and bottomed at -$344.3 million in Q1 2026.
• The 5-year median for Cash from Investing Activities is $2.5 million (2023), against an average of -$48.0 million.
• Across the five-year window, Cash from Investing Activities jumped 497.66% in 2023 and slumped 21736.0% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at $22.6 million in 2022, then plunged by 100.22% to -$50000.0 in 2023, then slumped by 21736.0% to -$10.9 million in 2024, then tumbled by 2907.79% to -$328.4 million in 2025, then declined by 4.84% to -$344.3 million in 2026.
• Per Business Quant, the three latest PRAX Cash from Investing Activities figures stand at -$344.3 million (Q1 2026), -$328.4 million (Q4 2025), and $50.4 million (Q3 2025).